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Iodine has a major role in the physiology and pathophysiology of the thyroid gland. It is 
transported into the thyroid by the sodium-iodide symporter (NIS), stimulated by thyroid 
stimulating hormone (TSH). This mechanism forms the base of thyroid scintigraphy with 
radioactive iodine and pertechnetate. Radioactive iodine is transported inside the gland by 
the same NIS as cold iodine and will be organified into thyroid hormones. In the first years of 
thyroid scintigraphy, radioiodine-131 (131I) was used for treatment as well as for imaging 
purposes. Due to its radiotoxic nature (beta particle emission) and its high energy gamma 
rays, it is not an ideal compound to use for diagnostic imaging. Another radioactive isotope of 
iodine can be used: 123I, a pure gamma emitter with consequently few radiotoxic side effects 
and an energy suited for conventional gamma camera imaging. However, it is very expensive 
and carries more radiation burden to the patient due to its longer effective half-life in 
comparison with 99mTcO4- (pertechnetate). Therefore it is not suited for daily clinical use. 
Nowadays pertechnetate is mostly used for diagnostic scintigraphy. It is also a pure gamma 
emitter with even better energy characteristics for gamma camera imaging. Although it is 
transported by the same NIS as iodine, it will not be organified. 
Hyperthyroidism in the cat is the most common indication for thyroid scintigraphy. The 
scintigraphic diagnosis is based on visual inspection and/or quantitative analysis of the data. 
Visually higher uptake in the thyroid compared to the salivary glands is typical for 
hyperthyroidism. A ratio calculated between pertechnetate uptake in the salivary glands and 
thyroid lobes and percentage uptake of the injected activity in the thyroid are two methods 
used in the quantitative analysis. Subsequent treatment of these animals with 131I is 
nowadays common practice. The majority of cats are cured with one injection. The amount of 
activity needed is based on gland size and volume, amount of activity accumulated in the 
thyroid and clinical parameters (severity of symptoms and TT4). Patient based dose 
estimation is for practical reasons not commonly performed in veterinary medicine and this 
practice is still a matter of debate in human medicine.  
Five percent of the cats needs a second injection. Five to 30% (depending on the literature 
source) becomes hypothyroid, but only a minority develops clinical signs of hypothyroidism. 
Up till now, no exact reason has been found to explain these variable treatment results. 
Several causes can be put forward such as the amount of injected activity and preclinical 
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parameters (less severe disease, prexisting kidney failure, prior treatment with antithyroid 
drugs, individual differences in thyroid kinetics). Bilateral involvement has been incriminated 
as a risk factor for development of hypothyroidism in cats.  
Thyroid scintigraphy is also of use in the diagnosis of primary hypothyroidism in dogs. In 
these animals lower uptake (ratio thyroid to salivary gland) or no uptake is pathognomonic. 
However, in some early cases of immune mediated thyroiditis, uptake may be normal or 
even increased. When congenital organification deficits are suspected, radioiodine should be 
used as pertechnetate will not be organified. Drug induced hypothyroidism will manifest as 
decreased or increased uptake of pertechnetate depending on the drug and the length of 
treatment. Secondary hypothyroidism can be differentiated from primary by scintigraphy after 
stimulation with TSH.  
Thyroid scintigraphy is also of importance in the management of thyroid tumours. Depending 
on the degree of (de)differentiation of the tumour cells and associated expression of the NIS, 
uptake of pertechnetate will be absent or present. This has consequences for treatment 
options as only those tumours with pertechnetate uptake are possible candidates for 
radioiodine therapy. In human medicine, research on re-differentiating agents and gene 
manipulation to induce NIS expression is blooming business. The uptake of pertechnetate in 
thyroid tumours is distinctive. If uptake is evident, it will often be highly heterogeneous. In 
addition to regular planar imaging, tomographic studies can help in staging the tumour. Pulmonary 
foci of increased uptake are also taking up radioiodine and therapeutically benefit in the 
same way as the primary tumour of the radioiodine treatment. In some patients uptake in 
metastases is suppressed by the primary tumour and will become visible after its removal. 
Therefore, in humans debulking surgery is followed by radioiodine treatment in order to 
eradicate all thyroid tissue. Afterwards, these patients receive thyroid hormone 
supplementation. Monitoring therapy results with 131I whole body imaging is combined with 
plasma thyroglobuline measurements. Patients in remission will have no foci of increased 
uptake on the scintigraphic images and will have low thyroglobulines. The moment one of the 
parameters becomes abnormal, relapse is suspected. The major drawback of radioiodine 
treatment is the hospitalization time required due to radioprotective issues. Release criteria 
vary enormously between countries depending on local and national regulations. This results 
in a variable hospitalization time among institutions. International harmonization would be 
welcome in order to balance safety limits with animal welfare. 
The most important factor that governs the amount of radiation emitted, is the amount of 
injected activity. A lower efficacious dose will reduce the surface dose-emission rate, i.e. 
radioactivity found in excreta and on the fur and paws, as well as hospitalization time 
respecting the ALARA (As low as Reasonable Achievable) principle. In this regard, 
administration of recombinant human thyroid stimulating hormone (rhTSH) to stimulate iodine 
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turnover may be an interesting compound. It is mainly used to reduce symptoms of 
hypothyroidism when human thyroid cancer patients are off thyroid hormone 
supplementation prior to the follow up whole body scan. rhTSH can also be used to increase 
uptake of radioiodine in the thyroid tissue, thus requiring a lower amount of activity. This has 
been demonstrated in humans and is under investigation in animals. 
Further, pertechnetate scintigraphy can be indicated to identify the origin of cervical masses. 
Normal aspect and uptake of thyroid lobes rule out thyroid involvement and since salivary 
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